Clusterin confers resistance to TNF-alphainduced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression

Journal of Chemotherapy

Volumn 24, Issue 6, 2012, Pages 348-357

  Wang, Yu ^a   Wang, Xingang ^a   Zhao, Hui ^b   Liang, Bo ^b   Du, Qihang ^b  

^a QINGDAO UNIVERSITY   (China)

^b Shandong Provincial Owned Hospital   (China)

Author keywords

Breast cancer; Clusterin; NF kappaB; TNF alpha

Indexed keywords

CLUSTERIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN P53; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; WILD TYPE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTERIN; DOWN-REGULATION; FEMALE; GENE SILENCING; HUMANS; MCF-7 CELLS; MUTANT PROTEINS; NEOPLASM PROTEINS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84870810356     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000049     Document Type: Article

References (34)

1. de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry. 1990;29:5380-9.
2. Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci. 2000;25:95-8.
3. Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol. 2002;34:1430-48.
4. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analysis of nuclear clusterin: a cell death protein. J Biol Chem. 2003;278:11590-600.
5. 2zdepletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ. 2005;12:101-4.
6. Redondo M, Villar E, Torres-Muñoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol. 2000;157:393-9.
7. Yom CK, Woo HY, Min SY, Kang SY, Kim HS. Clusterin overexpression and relapse-free survival in breast cancer. Anticancer Res. 2009;29:3909-12.
8. Li J, Jia L, Zhao P, Jiang Y, Zhong S, Chen D. Stable knockdown of clusterin by vectorbased RNA interference in a human breast cancer cell line inhibits tumour cell invasion and metastasis. J Int Med Res. 2012;40:545-55.
9. Trougakos IP, Gonos ES. Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res. 2006;40:1324-34.
10. 2-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res. 2004;64:6174-82.
11. Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, Yu D, et al. Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res. 2004;64:3126-36.
12. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006;13:12-9.
13. Flanagan L, Whyte L, Chatterjee N, Tenniswood M. Effects of clusterin over-expression on metastatic progression and therapy in breast cancer. BMC Cancer. 2010;10:107.
14. So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther. 2005;4:1837-49.
15. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361-71.
16. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45-65.
17. Danial NN, Korsmeyer SJ. Cell death. Critical control points. Cell. 2004;116:205-19.
18. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell. 2007;12:445-56.
19. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev. 2006;210:171-86.
20. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25:6680-4.
21. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3:221-7.
22. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 1995;376:167-70.
23. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72:1605-21.
24. Giri DK, Aggarwal BB. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem. 1998, 273:14008-14.
25. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNFa-induced apoptosis through Akt/PI3K/NF-kB activation and IL-6/Mcl-1 overexpression. Mol Cancer. 2011;10:106.
26. Wu J, Shao ZM, Shen ZZ, Lu JS, Han QX, Fontana JA, et al. Significance of apoptosis and apoptotic-related proteins, Bcl-2, and Bax in primary breast cancer. Breast J. 2000;6:44-52.
27. Mattson MP, Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest. 2001;107:247-54.
28. Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol. 2003;22:875-81.
29. Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, et al. Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int. 2003;92:463-9.
30. July LV, Beraldi E, So A, Fazli L, Evans K, English JC, et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther. 2004;3:223-32.
31. Santilli G, Aronow BJ, Sala A. Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J Biol Chem. 2003;278:38214-9.
32. Essabbani A, Margottin-Goguet F, Chiocchia G. Identification of clusterin domain involved in NF-kappaB pathway regulation. Biol Chem. 2010;285:4273-7.
33. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008,27:6398-406.
34. Deng X, Ruvolo P, Carr B, May EV, Jr. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA. 2000;97:1578-3.